On a disclosed annual basis, Neuromeka's sales rose from KRW 9.75 billion in 2022 to KRW 13.7 billion in 2023 (up 40.9% year on year) and KRW 25.3 billion in 2024 (up 83.9%), making 2024 the largest year in the 2022 to 2025 span. Sales fell 25.0% to KRW 19 billion in 2025.
The operating loss was KRW 7.8 billion in 2022, KRW 14.8 billion in 2023, KRW 19 billion in 2024 and KRW 14.9 billion in 2025, so the company has posted operating losses for four consecutive years from 2022 to 2025.
Even in 2024, the year of highest sales, the operating loss was the largest in the period at KRW 19 billion, and the operating margin was -75.2%. The operating margin was lowest in 2023 at -107.9% and was -78.4% in 2025.
Net loss attributable to controlling shareholders grew from KRW 8.2 billion in 2022 to KRW 17.7 billion in 2023 and KRW 16.7 billion in 2024, and reached KRW 22 billion in 2025, the largest of the four years.
Net loss including non-controlling interests was KRW 16.8 billion in 2024, a different figure from the controlling-shareholder loss of KRW 16.7 billion, so the two should be read separately.
Operating cash flow was -KRW 8 billion in 2022, -KRW 12.4 billion in 2023, -KRW 21.9 billion in 2024 and -KRW 11.4 billion in 2025, an outflow in every year.
The debt-to-equity ratio rose from 10.3% in 2022 to 297.9% in 2023 and 776.1% in 2024 before easing to 557.6% in 2025, when total equity was KRW 13.9 billion and total liabilities were KRW 77.5 billion.
On a quarterly basis, sales peaked at KRW 7.87 billion in the fourth quarter of 2025 (up 75.9% from the prior quarter), then fell to KRW 2.99 billion, KRW 2.82 billion and KRW 2.78 billion in the first three quarters of 2026, and third-quarter 2026 sales were down 37.9% year on year.
Over the same span the operating loss went from KRW 3.16 billion in the third quarter of 2025 to KRW 3.51 billion, KRW 4.31 billion, KRW 5.27 billion and KRW 7 billion in the third quarter of 2026, five consecutive loss quarters with a widening gap.
The controlling-shareholder net loss in the first quarter of 2026 was KRW 25.6 billion, far above that quarter's operating loss of KRW 4.31 billion, and how much non-operating items explain that gap should be checked against the detailed filings.
The combined controlling-shareholder net loss for the last four quarters (fourth quarter 2025 to third quarter 2026) was KRW 43.1 billion.